Intranasal corticosteroids (INSs) are the most effective treatment for allergic rhinitis (AR), especially in terms of relieving nasal congestion. However, INS safety and efficacy data in children younger than 6 years are limited.
In a 4-week, multicenter, double-blind, parallel-group study, 474 patients were randomized to receive triamcinolone acetonide (chemical formula on the right) aqueous nasal spray (TAA AQ), 110 microg once daily, or placebo.
Safety measures included reports of adverse events, morning serum cortisol levels before and after cosyntropin infusion, and growth as measured using office stadiometry.
Adverse event rates were comparable between treatment groups. There was no significant change in serum cortisol levels after cosyntropin infusion.
The authors concluded that the use of TAA AQ, 110 microg once daily, for up to 6 months offers a favorable efficacy to safety ratio in children aged 2 to 5 years with perennial AR.
Medications for Allergic Rhinitis. See more Mind Maps of Allergic Rhinitis.
Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Weinstein S, Qaqundah P, Georges G, Nayak A. Ann Allergy Asthma Immunol. 2009 Apr;102(4):339-47.
Allergic Rhinitis: A Short Review
Mind Maps: Allergic Rhinitis
Mnemonics: Allergic Rhinitis
Growth Velocity Reduced by 0.27 cm with Fluticasone Nasal Spray daily for 1 years in Prepubescent Children http://buff.ly/1jNf4Ny
Image source: Triamcinolone, Wikipedia, the free encyclopedia, public domain.